ORLANDO, Fla. – Johnson & Johnson’s long-awaited single-dose vaccine could soon go before federal regulators, seeking emergency use authorization.
The company announced Friday that the vaccine developed by the drug making arm of its company, Janssen, is 66% effective overall at preventing moderate to severe illness and 85% effective against preventing the most serious symptoms. [TRENDING: Video shows deputy Tasing student | How to get the vaccine in Fla. | NASA tests new moon rocket] There was some geographic variation.
The vaccine worked better in the U.S. — 72% effective against moderate to severe COVID-19 – compared to 57% in South Africa, where it was up against an easier-to-spread mutated virus.